Pan-cancer analysis of TIM-3 transcriptomic expression reveals high levels in pancreatic cancer and interpatient heterogeneity.

Jungah LimRazelle KurzrockDaisuke NishizakiHirotaka MiyashitaJacob J AdashekSuzanna LeeSarabjot PablaMary NeslineJeffrey M ConroyPaul DePietroScott M LippmanShumei Kato

Published in: Cancer medicine (2023)

These observations indicate that TIM-3 RNA expression is heterogeneous, but more common in pancreatic cancer and in tumors exploiting PD-L1 and CTLA-4 checkpoints. Clinical trials with patient selection for matched immune-targeted combinations may be warranted.

Keyphrases

poor prognosis
clinical trial
single cell
papillary thyroid
binding protein
case report
long non coding rna
cancer therapy
rna seq
drug delivery
phase iii